Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.
1. A combined therapy method of treating a breast cancer disease in a patient who has failed prior therapy with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody and an anti-VEGF antibody, wherein the breast cancer disease is characterized by an overexpression of the HER2 receptor protein, and wherein said method demonstrates tumor regression.
2. The method of claim 1 , wherein the patient is human.
3. The method of claim 2 , wherein the anti-VEGF antibody is bevacizumab.
4. The method of claim 2 wherein the anti-HER2 antibody is trastuzurmab.
5. A method of reducing metastasis of a breast cancer that was non-responsive to prior therapy with an anti-VEGF antibody in a patient, comprising administering to the patient effective amounts of an anti-VEGF antibody and an anti-HER2 antibody, whereby the co-administration of the anti-VEGF antibody and the anti-HER2 antibody effectively reduces metastasis, as quantified by real-time PCR, and wherein the cancer is characterized by an overexpression of the HER2 receptor protein.
6. The method of claim 5 , wherein the patient is human.
7. The method of claim 6 , wherein the anti-VEGF antibody is bevacizumab.
8. The method of claim 6 , wherein the anti-HER2 antibody is trastuzumab.
9. The method of claim 5 , wherein the reduction of metastasis is in lung metastasis.